Thr66
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.2
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr66  -  osteopontin (human)

Site Information
NAVssEEtNDFKQET   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 455707

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 2 , 3 , 4 , 5 , 6 )
Disease tissue studied:
lung cancer ( 3 ) , non-small cell lung cancer ( 3 ) , melanoma skin cancer ( 2 )
Relevant cell line - cell type - tissue:

References 

1

Li H, et al. (2015) Site-specific structural characterization of O-glycosylation and identification of phosphorylation sites of recombinant osteopontin. Biochim Biophys Acta 1854, 581-91
25450502   Curated Info

2

Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615
25850435   Curated Info

3

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

4

Schreiber TB, et al. (2010) An integrated phosphoproteomics work flow reveals extensive network regulation in early lysophosphatidic acid signaling. Mol Cell Proteomics 9, 1047-62
20071362   Curated Info

5

Christensen B, Petersen TE, Sørensen ES (2008) Post-translational modification and proteolytic processing of urinary osteopontin. Biochem J 411, 53-61
18072945   Curated Info

6

Christensen B, et al. (2005) Post-translationally modified residues of native human osteopontin are located in clusters: identification of 36 phosphorylation and five O-glycosylation sites and their biological implications. Biochem J 390, 285-92
15869464   Curated Info